Glutathione therapy is evidence-based cellular support that works at the molecular level, and it sits within our complete IV nutritional therapy program
The compounds used are Ferrostain-1 (Fer-1) (S7243, Selleck), Deferoxamine (DFO) (D9533, Sigma), Propidium iodide (PI) (P4170, Sigma), BODIPY581/591 C11 (D3861, ThermoFisher), Lipofectamine 2000 (11668500, Invitrogen), DCFH2-DA (D6883, Sigma), Cystine (30200, Sigma), Homocysteine (Hcy) (H4628, Sigma), Cystathionine (Cta) (C7505, Sigma), S -adenosylmethionine (SAM) (A7007, Sigma), S -adenosylhomocysteine (SAH) (A9384, Sigma), Methionine (Met) (M9625, Sigma), FIDAS-5 (HY-136144, MCE), PF-9366 (S0435, Selleck), Adenosine Dialdehyde (ADOX) (S8608, Selleck), Mitoguazone (MGBG) (HY-15763, MCE), Erastin (HY-15763, MCE), Imidazole Ketone Erastin (IKE) (S8877, Selleck), Mito-TEMPO (HY-112879, MCE), Oligomycin (HY-N6782, MCE), Antimycin A (MS0070, MaoKangBio), Coenzyme Q4 (C921665, Maklin), RSL3 (HY-100218A, MCE), Doxorubicin (DOX) (HY-15142, MCE), Apoptosis Inducer Kit (TNF-/SM-164, C0006, Beyotime), Necroptosis Inducer Kit (TNF-/SM-164/Z-VAD-FMK, C1058, Beyotime), Annexin V-FITC Apoptosis Detection Kit (C1062, Beyotime), LPS (Sigma, L2630), Nigericin (HY-100381, MCE), Methylnitronitrosoguanidine (MNNG) (HY-128612, MCE), alpha-phenyl-tert- N -butylnitrone (PBN, B100838, Aladdin), iFSP1 (HY-136057, MCE), MitoTracker (M7512, Thermo), Total Glutathione Assay Kit (S0052, Beyotime), Cysteine Content Assay Kit (D799571-0050, Sangon Biotech), LDH Cytotoxicity Assay Kit (C0016, Beyotime), CoQ10 Test Kit (PM23627, PERFEMIKER), Mevalonate ELISA Kit (YX-132201M, Sino Best Biological Technology), Tyrosine Assay Kit (ab185435, Abcam), In Situ Cell Death Detection (TUNEL) Kit (11684817910, Roche), S -adenosylmethionine (SAM) ELISA Kit (BY-JZF0361, BYabscience, Nanjing, China), S -adenosylhomocysteine (SAH) ELISA Kit (BY-JZF0362, BYabscience), Mito Stress Test Kits (101706-100, Agilent)
Functional clinicians don't just ask, What pill can we use?they ask life-shaping questions that connect digestion, immunity, environment, and energy
The dispensability of ERO1A in healthy cells, in stark contrast with the relevance of ERO1A in TNBC, makes ERO1A an ideal target for TNBC therapy
[99] showed that medium-dose VitC (0.5 g kg 1 ) could abrogate cetuximab resistance in vivo and suggested sodium-dependent vitamin C transporter SVCT2 as a potental marker for enhancing efficacy of the combination treatment of VitC and cetuximab in KRAS-mutant CRC patients
Biological Characteristics of Carbon-Ion Therapy
